INSM
Price
$190.95
Change
-$3.44 (-1.77%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
41.46B
98 days until earnings call
Intraday BUY SELL Signals
INTS
Price
$0.48
Change
-$0.03 (-5.88%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
30.61M
119 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INSM vs INTS

Header iconINSM vs INTS Comparison
Open Charts INSM vs INTSBanner chart's image
Insmed
Price$190.95
Change-$3.44 (-1.77%)
Volume$41.23K
Capitalization41.46B
Intensity Therapeutics
Price$0.48
Change-$0.03 (-5.88%)
Volume$4.05K
Capitalization30.61M
INSM vs INTS Comparison Chart in %
INSM
Daily Signal:
Gain/Loss:
INTS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
INSM vs. INTS commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a StrongBuy and INTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (INSM: $194.39 vs. INTS: $0.51)
Brand notoriety: INSM and INTS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 77% vs. INTS: 113%
Market capitalization -- INSM: $41.46B vs. INTS: $30.61M
INSM [@Biotechnology] is valued at $41.46B. INTS’s [@Biotechnology] market capitalization is $30.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileINTS’s FA Score has 1 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • INTS’s FA Score: 1 green, 4 red.
According to our system of comparison, both INSM and INTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 4 TA indicator(s) are bullish while INTS’s TA Score has 6 bullish TA indicator(s).

  • INSM’s TA Score: 4 bullish, 4 bearish.
  • INTS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, INTS is a better buy in the short-term than INSM.

Price Growth

INSM (@Biotechnology) experienced а +4.02% price change this week, while INTS (@Biotechnology) price change was -10.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

INSM is expected to report earnings on Feb 19, 2026.

INTS is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($41.5B) has a higher market cap than INTS($30.6M). INSM YTD gains are higher at: 181.561 vs. INTS (-70.909). INTS has higher annual earnings (EBITDA): -12.56M vs. INSM (-938.1M). INSM has more cash in the bank: 1.86B vs. INTS (2.22M). INTS has less debt than INSM: INTS (125K) vs INSM (576M). INSM has higher revenues than INTS: INSM (398M) vs INTS (0).
INSMINTSINSM / INTS
Capitalization41.5B30.6M135,621%
EBITDA-938.1M-12.56M7,472%
Gain YTD181.561-70.909-256%
P/E RatioN/AN/A-
Revenue398M0-
Total Cash1.86B2.22M83,800%
Total Debt576M125K460,800%
FUNDAMENTALS RATINGS
INSM: Fundamental Ratings
INSM
OUTLOOK RATING
1..100
75
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
PROFIT vs RISK RATING
1..100
3
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
43

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
INSMINTS
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
61%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 17 days ago
71%
Declines
ODDS (%)
Bearish Trend 10 days ago
73%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
INSM
Daily Signal:
Gain/Loss:
INTS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PASG9.381.68
+21.82%
Passage Bio Inc
QTRX5.220.22
+4.40%
Quanterix Corp
SHW344.72-0.36
-0.10%
Sherwin-Williams Company (The)
CRML9.71-0.06
-0.61%
Critical Metals Corp
QLYS150.05-3.75
-2.44%
Qualys

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
+0.36%
THAR - INSM
74%
Closely correlated
-2.42%
ROIV - INSM
42%
Loosely correlated
+2.01%
AXON - INSM
40%
Loosely correlated
-0.47%
ARRY - INSM
40%
Loosely correlated
-8.69%
VRDN - INSM
40%
Loosely correlated
+1.79%
More

INTS and

Correlation & Price change

A.I.dvisor tells us that INTS and INSM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and INSM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
+31.28%
INSM - INTS
31%
Poorly correlated
+0.36%
ACAD - INTS
28%
Poorly correlated
+1.73%
CCCC - INTS
27%
Poorly correlated
N/A
OABI - INTS
25%
Poorly correlated
-2.48%
GPCR - INTS
25%
Poorly correlated
+3.03%
More